• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ProPhase Labs Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    11/26/25 2:15:29 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRPH alert in real time by email
    false 0000868278 0000868278 2025-11-24 2025-11-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of

    The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): November 24, 2025

     

    PROPHASE LABS, INC.

    (Exact name of Company as specified in its charter)

     

    Delaware

     

    000-21617

     

    23-2577138

    (State or other jurisdiction

    of incorporation )

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    626 RXR Plaza, 6th Floor

    Uniondale, New York

     

    11556

    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (516) 903-0763

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14(d)-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities Registered Pursuant to Section 12(b) of the Exchange Act:

     

    Title of Each Class   Trading Symbol   Name of Each Exchange of Which Registered
    Common Stock, par value $0.0005   PRHP   Nasdaq Capital Markets

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders

     

    On November 24, 2025, ProPhase Labs, Inc. (the Company) held a Special Meeting of Stockholders. As of the record date, 43,979,017 shares of common stock were outstanding and entitled to vote. A total of 29,829,274 shares were represented in person or by proxy, which satisfied the quorum requirements for the meeting under the Company’s bylaws.

     

    Stockholders considered six proposals. Each proposal received the requisite approval based on the votes cast at the meeting. The voting results reflect strong participation and consistent levels of support across all matters presented. The certified results were as follows:

     

    Proposal 1: Clarification that the Company May Acquire Digital Assets

    For: 15,250,528

    Against: 582,008

    Abstain: 25,697

    Broker non votes: 13,971,041

     

    Proposal 2: Creation of a New Class of Digital Treasury Shares

    For: 15,194,678

    Against: 615,619

    Abstain: 47,936

    Broker non votes: 13,971,041

     

    Proposal 3: Authorization of the Potential Issuance of Digital Tokens

    For: 15,107,219

    Against: 618,878

    Abstain: 132,136

    Broker non votes: 13,971,041

     

    Proposal 4: Authority to Effect One or More Reverse or Forward Stock Splits

    For: 27,961,611

    Against: 1,791,298

    Abstain: 76,365

     

    Proposal 5: Conditional Amendment to Increase Authorized Common Stock

    For: 26,259,925

    Against: 3,207,117

    Abstain: 362,232

     

    Proposal 6: Approval of Adjournment of the Special Meeting
    For: 27,932,553

    Against: 1,763,485

    Abstain: 133,236

     

    All six proposals were approved based on the votes cast. Proposal 4, which authorizes the Company to effect one or more reverse or forward stock splits, also satisfied the approval requirements for charter amendments under Delaware law. Under the General Corporation Law of the State of Delaware, charter amendments require the affirmative vote of a majority of the outstanding shares entitled to vote. Proposal 4 received 27,961,611 votes in favor out of 43,979,017 shares outstanding, which represents approximately 63.57 percent of the outstanding shares and exceeds the required threshold by a significant margin. The Company appreciates the participation and support of its stockholders.

     

    Item 9.01 Financial Statements and Exhibits

     

    (d) Exhibits

    None.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    ProPhase Labs, Inc.  
         
    By: /s/ Ted Karkus  
      Ted Karkus  
      Chairman of the Board and Chief Executive Officer  
         
    Date: November 26, 2025  

     

     

     

    Get the next $PRPH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRPH

    DatePrice TargetRatingAnalyst
    1/14/2022$12.00 → $15.00Buy
    HC Wainwright & Co.
    12/20/2021$12.00Buy
    HC Wainwright & Co.
    10/13/2021Buy → Neutral
    Dawson James
    More analyst ratings

    $PRPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Join ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on December 1

    UNIONDALE, NY, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) is pleased to invite investors to a webinar on December 1, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature ProPhase Lab's Chairman and CEO Ted Karkus. Attendees will gain an in-depth look at ProPhase's dynamic portfolio of high-growth healthcare assets spanning molecular diagnostics, genomics, and consumer health. Karkus will highlight recent milestones, including full U.S. patent approval and clinical validation of its BE-Smart™ Esophageal Cancer Test, a groundbreaking diagnostic designed for early cancer detection in a $7–14 billion addressable market. The presentatio

    11/26/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.

    ProPhase Labs in discussions for strategic initiative to realize significant underlying value in the Company. Voting for Current Proxy Critically Important. Crown Medical Achieves Final Hurdle. Appointed Special Counsel to Launch Litigation Against Insurance Companies. First Settlement Completed. Reiterates $50 MILLION Net A/R Goal Next-Phase Commercialization of BE-Smart™ Underway Following Landmark Study Published in the Official Journal of the American College of Gastroenterology UNIONDALE, NY, Nov. 19, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) (the "Company" or "ProPhase") today announced it is in M&A related discussions not connected to a crypto treasury strategy.

    11/19/25 8:13:06 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19

    UNIONDALE, NY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH) (the "Company" or "ProPhase"), a next generation biotech, genomics and consumer products company, announced today that they will be presenting third quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on November 19, 2025, at 2:00 pm EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register using the link below. After the event, a rep

    11/18/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on ProPhase Labs with a new price target

    HC Wainwright & Co. reiterated coverage of ProPhase Labs with a rating of Buy and set a new price target of $15.00 from $12.00 previously

    1/14/22 6:36:15 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on ProPhase Labs with a new price target

    HC Wainwright & Co. initiated coverage of ProPhase Labs with a rating of Buy and set a new price target of $12.00

    12/20/21 6:25:15 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase downgraded by Dawson James

    Dawson James downgraded ProPhase from Buy to Neutral

    10/13/21 10:48:44 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    SEC Filings

    View All

    ProPhase Labs Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ProPhase Labs, Inc. (0000868278) (Filer)

    11/26/25 2:15:29 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - ProPhase Labs, Inc. (0000868278) (Filer)

    11/25/25 4:30:50 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ProPhase Labs, Inc. (0000868278) (Filer)

    11/25/25 4:30:50 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Leadership Updates

    Live Leadership Updates

    View All

    Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

    6/18/25 11:19:00 AM ET
    $CATX
    $CGON
    $GALT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports

    GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and consumer products company, today announced the appointment of Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company's expansion into consumer-centered health and wellness products. As COO, Hollenshead will focus on accelerating ProPhase Labs' consumer-facing strategy, leveraging his deep expertise in direct-to-consumer growth, subscription models, digital marketing, and audience monetization to position the company as a leader in science-backed health solutions. The Company plans to provide additional updat

    2/18/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Unveils Project ZenQ-AI

    Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company's state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (W

    4/16/24 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Abenante Carolina

    3 - ProPhase Labs, Inc. (0000868278) (Issuer)

    11/10/25 9:55:56 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO & CHAIRMAN Karkus Ted William

    4 - ProPhase Labs, Inc. (0000868278) (Issuer)

    9/11/25 4:05:22 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Operating Officer Hollenshead Stuart

    4 - ProPhase Labs, Inc. (0000868278) (Issuer)

    2/21/25 5:15:08 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

    SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

    3/19/24 4:18:00 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

    SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

    4/5/23 4:37:55 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

    SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

    4/4/23 4:25:33 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Financials

    Live finance-specific insights

    View All

    ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.

    ProPhase Labs in discussions for strategic initiative to realize significant underlying value in the Company. Voting for Current Proxy Critically Important. Crown Medical Achieves Final Hurdle. Appointed Special Counsel to Launch Litigation Against Insurance Companies. First Settlement Completed. Reiterates $50 MILLION Net A/R Goal Next-Phase Commercialization of BE-Smart™ Underway Following Landmark Study Published in the Official Journal of the American College of Gastroenterology UNIONDALE, NY, Nov. 19, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) (the "Company" or "ProPhase") today announced it is in M&A related discussions not connected to a crypto treasury strategy.

    11/19/25 8:13:06 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19

    UNIONDALE, NY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH) (the "Company" or "ProPhase"), a next generation biotech, genomics and consumer products company, announced today that they will be presenting third quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on November 19, 2025, at 2:00 pm EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register using the link below. After the event, a rep

    11/18/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025

    ProPhase Delivers Significant Operational and Financial Improvements, Advances Multiple Non-Dilutive Liquidity Initiatives, and Targets Transformational Growth Catalysts Company granted key U.S. patent on BE-Smart™ Esophageal Adenocarcinoma Risk Assessment test (August 2025) Company to hold a virtual conference call Wednesday, August 13, 2025, at 2:00 PM ET UNIONDALE, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a diversified diagnostics, genomics, and consumer healthcare company, today reported financial and operational results for the three and six months ended June 30, 2025. Ted Karkus, CEO of ProPhase Labs, will present to s

    8/13/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care